文献速递肿瘤 PET/CT

18F-氟昔洛韦PET/CT指导前列腺切除术后复发前列腺癌的挽救性放疗决策

Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance.
PubMed 文献 · J Nucl Med · 2021-01-30

本研究将前列腺切除术后PSA可检测的患者随机分为仅常规影像组和常规影像联合18F-氟昔洛韦PET/CT组,在放疗前进行决策。结果显示18F-氟昔洛韦PET/CT显著提高了复发灶检出率,并改变了35.4%患者的整体放疗决策和32.0%患者的放疗野,差异有统计学意义。

要点

  • 18F-氟昔洛韦PET/CT全身阳性率显著高于常规影像(79.7% vs. 13.9%)。
  • 35.4%患者因PET/CT改变整体放疗决策,5.1%因检出盆腔外病变取消放疗。
  • 32.0%计划放疗的患者放疗野发生改变,决策改变具有统计学意义。

核心结论

  • 18F-氟昔洛韦PET/CT显著改变了前列腺切除术后复发前列腺癌患者的挽救性放疗决策。

研究设计与样本

  • 随机对照研究,患者为前列腺切除术后PSA可检测者,随机分为仅常规影像组(A组)和常规影像联合18F-氟昔洛韦PET/CT组(B组),在放疗前进行影像评估。

主要发现

  • 18F-氟昔洛韦PET/CT阳性率显著高于常规影像:全身79.7% vs. 13.9%(P < 0.001),前列腺床69.6% vs. 5.1%(P < 0.001),盆腔淋巴结38.0% vs. 10.1%(P < 0.001)。
  • 75例最终决定放疗的患者中24例(32.0%)放疗野改变,决策改变和放疗野改变均具有统计学意义(P < 0.001)。
  • 有无放疗决策改变的患者间,PET时平均PSA差异有统计学意义(P = 0.033)。

临床怎么用

  • 对于前列腺切除术后生化复发患者,在挽救性放疗前可考虑行18F-氟昔洛韦PET/CT以指导放疗决策和靶区制定。

局限性

  • 18F-氟昔洛韦PET/CT指导对放疗后临床结局的影响尚在进一步分析中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Imaging with novel PET radiotracers has significantly influenced radiotherapy decision making and radiation planning in patients with recurrent prostate cancer (PCa). The purpose of this analysis was to report the final results for management decision changes based on 18F-fluciclovine PET/CT findings and determine whether the decision change trend remained after completion of accrual. Methods: Patients with detectable prostate-specific antigen (PSA) after prostatectomy were randomized to undergo either conventional imaging (CI) only (arm A) or CI plus 18F-fluciclovine PET/CT (arm B) before radiotherapy. In arm B, positivity rates on CI and 18F-fluciclovine PET/CT for detection of recurrent PCa were determined. Final decisions on whether to offer radiotherapy and whether to include only the prostate bed or also the pelvis in the radiotherapy field were based on 18F-fluciclovine PET/CT findings. Radiotherapy decisions before and after 18F-fluciclovine PET/CT were compared. The statistical significance of decision changes was determined using the Clopper-Pearson (exact) binomial method. Prognostic factors were compared between patients with and without decision changes. Results: All 165 patients enrolled in the study had standard-of-care CI and were initially planned to receive radiotherapy. Sixty-three of 79 (79.7%) patients (median PSA, 0.33 ng/mL) who underwent 18F-fluciclovine PET/CT (arm B) had positive findings. 18F-Fluciclovine PET/CT had a significantly higher positivity rate than CI did for the whole body (79.7% vs. 13.9%; P < 0.001), prostate bed (69.6% vs. 5.1%; P < 0.001), and pelvic lymph nodes (38.0% vs. 10.1%; P < 0.001). Twenty-eight of 79 (35.4%) patients had the overall radiotherapy decision changed after 18F-fluciclovine PET/CT; in 4 of 79 (5.1%), the decision to use radiotherapy was withdrawn because of extrapelvic disease detected on 18F-fluciclovine PET/CT. In 24 of 75 (32.0%) patients with a final decision to undergo radiotherapy, the radiotherapy field was changed. Changes in overall radiotherapy decisions and radiotherapy fields were statistically significant (P < 0.001). Overall, the mean PSA at PET was significantly different between patients with and without radiotherapy decision changes (P = 0.033). Conclusion:18F-Fluciclovine PET/CT significantly altered salvage radiotherapy decisions in patients with recurrent PCa after prostatectomy. Further analysis to determine the impact of 18F-fluciclovine PET/CT guidance on clinical outcomes after radiotherapy is in progress.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Abiodun-Ojo OA, Jani AB, Akintayo AA, et al. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance. J Nucl Med. 2021. PMID: 33517323. doi:10.2967/jnumed.120.256784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。